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will improve survival in children with high-risk solid tumors. Fif-
teen patients were enrolled from March 2000 to August 2004 with
a median age of 6 years (2–19). Each had received at least 2 courses
of chemotherapy prior to study enrollment. Patients (Table 1) had
the following diagnoses: recurrent Wilms tumor (n  5), high-risk
Ewing’s sarcoma (n  3), recurrent hepatoblastoma (n  2), re-
current retinoblastoma (n  2), recurrent germ cell tumor (n  2),
and undifferentiated sarcoma (n  1). Patients were prepared with
etoposide (800 mg/m2/day on 6, 5, 4), carboplatin (667 mg/
m2/day on 6, 5, 4), and cyclophosphamide (1800 mg/m2/day
on 3, 2) prior to the ﬁrst transplant, and melphalan (60 mg/
m2/day on8,7,6) and cyclophosphamide (500 mg/m2/day on
5, 4, 3, 2) prior to the second. Children received a median
of 3.86  108 TNC/Kg (2.3–9.4) prior to the ﬁrst transplant, and
4.1  108 (2.5–10.5) TNC/Kg prior to the second. Eight patients
were in complete remission and 7 were in partial remission at the
time of ﬁrst transplant. One patient received local radiation instead
of the second transplant due to parental preference. Following each
rescue, patients achieved an ANC 	 500 at a median of 13 days
(11–34) and 12 days (10–31), respectively. Patients achieved a
platelet count 	20,000 at a median of 22 days (13–37) and 37 days
(15–113), respectively. There was a median of 38 days between
rescues (29–49). Five patients received radiation therapy post-
transplant to relapse sites. There were no toxic deaths. Toxicity was
primarily hematopoietic. Nine of 15 are surviving, 2 with recurrent
disease following tandem therapy at a median follow-up of 22 months
(11–55). Relapses following transplant occurred at the primary site
(n  3), distant (n  3), and primary/distant (n  2). Five have died
from progressive disease; 1 from late pulmonary toxicity. We con-
clude that tandem stem cell transplant used as consolidation in pa-
tients with solid tumors is feasible, well tolerated, and offers the
potential for cure in some patients with high-risk disease (Table1).
Table 1. Patient Characteristics
Patient Diagnosis
Stage/
Location
Relapse
Site Prior
to SCT
Relapse Site
Following
SCT
Follow-up
Post
Transplant
1 Undifferentiated
sarcoma
Pelvis NED,
55 months
2 Ewing’s Pelvis Primary
site, lungs
PD, died -
39 months
3 Hepatoblastoma Stage IV Primary site Alive, stable
disease -
53 months
4 Wilms Recurrent
stage IV
Primary site,
lungs
NED,
45 months
5 Ewing’s Pelvis Primary
site, lungs
PD, died -
11 months
6 Wilms Recurrent
stage I
Liver NED,
49 months
7 Wilms Recurrent
stage III
Lungs CNS Alive, stable
disease -
38 months
8 Ewing’s Metastatic NED,
41 months
9 Hepatoblastoma Recurrent
stage IV
Primary site Lungs PD, died -
22 months
10 Germ cell
tumor
Stage IV Pulmonary
toxicity,
died -
19 months
11 Wilms Recurrent
stage II
Primary site Primary
site
NED,
27 months
12 Wilms Recurrent
stage III
Primary site Primary
site
PD, died -
12 months
13 Retinoblastoma Bilateral Sinus, orbit NED,
16 months
14 Retinoblastoma Bilateral Pineal Pineal PD, died -
11 months
15 Germ cell
tumor
Pineal Primary site NED,
13 months
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PHARMACOKINETICS (PK) OF 2 DOSING REGIMENS OF PALIFERMIN IN
PATIENTS (Pts) WITH HEMATOLOGIC MALIGNANCIES (HM) UNDER-
GOING HIGH-DOSE CHEMORADIOTHERAPY AND HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT)
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For patients (pts) with HM undergoing HSCT, oral mucositis
(OM) is a frequent and debilitating complication that negatively
impacts treatment outcomes, patient quality of life, and healthcare
resources. Palifermin reduces the incidence and duration of severe
OM in the HSCT setting. This phase 1 open-label study assessed
the PK of 2 palifermin dosing regimens. Methods: Pts were 18 to
76 years old with HM and a Karnofsky performance score 70%.
Palifermin was administered intravenously once daily as follows: 60
mcg/kg/day for 3 consecutive days on day 11, day 10, and day
9 before conditioning (total body irradiation [TBI]  etopo-
side  cyclophosphamide) and following HSCT on days 0, 1, and
2 (part A) and a single dose of 180 mcg/kg (part B) before condi-
tioning on day 11 and after HSCT on d 0. In part A (6 total
doses), PK parameters were assessed after the ﬁrst, third, fourth,
and sixth doses. In part B (2 total doses), assessments were made
after each dose administration (day 11 and day 0). Results: In
part A, 13 pts received palifermin; in part B, 12 pts received the
single dose on day 11 and 11 pts received the single dose on day
0. For both dosing regimens, palifermin concentrations declined
rapidly (98% decrease) in the ﬁrst 30 minutes postdose, followed
by a slight increase in mean concentrations between 1 and 4 hours
and then a terminal decay phase. Respective mean (SD) PK pa-
rameter values for the 2 dosing regimens are shown in Table 1. In
part A, mean AUC0-t values were comparable between doses 1 and
3 (within 15%) and 1 and 4 (within 1%). In part B, mean PK
parameter values were similar (within 10% of each other) between
doses 1 and 2. The mean AUC after the ﬁrst 180 mcg/kg dose in
part B was approximately 4-fold higher than that after the ﬁrst 60
mcg/kg dose in part A. Mean half-life values ranged between 3.3 to
5.7 hours in part A and the value was 5.4 hours in part B. Con-
clusions:The PK data in pts receiving HSCT were consistent with
approximately dose-linear PK in the dose range of 60 and 180
mcg/kg, with no observed accumulation, based on AUC, after 3
daily doses of 60 mcg/kg in this pt population in the HSCT setting
(Table1).
Table 1.
Dosing
Regimen
(Dosing Day) n
AUC0-t
(hr  ng/mL)
Mean (SD)
Clearance
(mL/hr/kg)
Mean (SD)
Vss (mL/kg)
Mean (SD)
Part A - 60 mcg/kg/day  3 consecutive days
1st dose (day 11) 9 to 13 34.3 (15.9) 1730a (497) 5320a (2330)
3rd dose (day 9) 13 39.8 (36.4) - -
4th dose (day 0) 11 to 13 34.8 (22.5) 2030a (862) 3870a (2080)
6th dose (day 2) 13 21.2 (15.1) - -
Part B - 180 mcg/kg/day  1 day
1st dose (day 11) 12 140 (50.9) 1460 (600) 4290 (3270)
2nd dose (day 0) 11 143 (71.8) 1770 (1290) 4270 (4700)
Accurate computations of clearance (CL) and volume of distribu-
tion at steady state (Vss) were not possible for some concentra-
tion-time proﬁles.
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THE FAILURE OF PROGNOSTIC MODELS (PM) FOR HODGKINS DISEASE
(HD) TO PREDICT OUTCOMES AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION (ASCT)
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PM have been developed for patients with advanced HD in an
effort to identify high-risk individuals for and predict outcomes of
ASCT. Four PM were evaluated in patients transplanted in our
program between 1993 and 2005. One hundred and thirteen pa-
tients with relapsed or refractory HD received ASCT. Forty-ﬁve
patients received a conditioning regimen of busulfan, melphalan,
and thiotepa (BuMelTT), whereas 68 patients received other stan-
dard conditioning regimens (SCR) including Cy/TBI/VP (23),
CBV (39), and other (6). Followup is 113 weeks for BuMelTT
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